Literature DB >> 1661415

Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved.

C Polychronakos1, U Janthly, J G Lehoux, M Koutsilieris.   

Abstract

Four transplantable cell lines (PA-I, II, III, and IV) derived from four Lobund-Wistar (L-W) rats that manifested spontaneous prostate cancer have demonstrated metastatic capacity in visceral organs. Interestingly, PA-III cells, when deposited over the scapula or calvarium of the Lobund-Wistar rat, could produce lytic and blastic reactions on rat skeleton. Since growth factors and growth factor receptors have been implicated in bone remodeling, cancer biology, and metastatic growth of cancer cells, we have examined 1) the effects of insulin and insulin-like growth factors (IGF-I and IGF-II) on the proliferation of PA-III cells; and 2) the presence of specific receptors for these peptides. IGF-I (0.5 to 100 ng/ml), IGF-II (0.5 to 100 ng/ml), and insulin (0.5 to 10 micrograms/ml) stimulated tritiated thymidine uptake and increased the number of PA-III cells in culture. Receptor studies demonstrated the presence of specific bindings sites for IGF-I and II but not for insulin. The number and affinity of the receptor sites were: IGF-I (nb = 675 fmol/100 g protein, Kd = 0.56 nmol) and IGF-II (nb = 225 fmol/100 g protein, Kd = 0.71 nmol). Molecular characterization of IGF binding sites by polyacrylamide gel electrophoresis under denaturing conditions indicated only the presence for the type I IGF receptor. The presence of the IGF-I receptor and the absence of IGF-II and insulin receptors are discussed in relation to the capacity of PA-III cells to produce bone lesions on the L-W rat.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661415     DOI: 10.1002/pros.2990190405

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.

Authors:  P Burfeind; C L Chernicky; F Rininsland; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.

Authors:  Jay H Fowke; Lauren Howard; Gerald L Andriole; Stephen J Freedland
Journal:  Eur Urol       Date:  2014-02-09       Impact factor: 20.096

3.  Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold.

Authors:  Minoru Kobayashi; Tomoya Mizuno; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Akinori Nukui; Hideyuki Abe; Yoshitatsu Fukabori; Masahiro Yashi; Takao Kamai
Journal:  Int J Clin Oncol       Date:  2019-08-22       Impact factor: 3.402

4.  Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton.

Authors:  C Reyes-Moreno; M Koutsilieris
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

Review 5.  Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.

Authors:  Jennifer Wu; Evan Yu
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

6.  Insulin-like growth factor-II receptor expression in normal and N-methyl-N'-nitro-nitrosoguanidine exposed cell lines: assessment by flow cytometry.

Authors:  W H Thornton; L Barnett; R S MacDonald
Journal:  In Vitro Cell Dev Biol       Date:  1993-02

Review 7.  Growth factors as mediators of androgen action during the development of the male urogenital tract.

Authors:  G R Cunha; B Foster; A Thomson; Y Sugimura; N Tanji; M Tsuji; N Terada; P W Finch; A A Donjacour
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 8.  Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta-analysis.

Authors:  Qingling Hua; Yanzhe Zhu; Hu Liu; Xiaobing Ye
Journal:  Int Urol Nephrol       Date:  2016-05-11       Impact factor: 2.370

9.  Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study.

Authors:  Jocelyn S Kasper; Yan Liu; Edward Giovannucci
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

10.  Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.

Authors:  Efstathia Papageorgiou; Nea Pitulis; Menelaos Manoussakis; Peter Lembessis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.